Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Austin Baraki

Obesity Medicine · Vineyard Health

View

Dr. Priya Jaisinghani

Obesity Medicine · NYU Langone

View

Dr. Jodi Nagelberg

Obesity Medicine · UCSD

View

Dr. Maria Fleseriu

Neuroendocrinology · OHSU Hospital

View

Dr. John Stafford

General Endocrinology · OSUMC

View

Dr. David Cohen

Thyroid · RU

View

Dr. Susan Spratt

Diabetes · Duke

View

Dr. James Findling

Adrenal Diseases · Froedtert

View

Dr. Anupam Kotwal

Thyroid · UNMC

View

Dr. William Young

Adrenal Diseases · Mayo Clinic College of Medicine

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    FBDr. Fernando Bril

    Dr. Fernando Bril

    Endocrinology · Obesity Medicine & Nutrition
    University of Alabama at Birmingham
    fernandob

    Research

    Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes

    2026

    Via JAMA Network Open

    Research

    Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

    2026

    Via Diabetes, Obesity & Metabolism

    Research

    Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

    2026

    Via Clinical Gastroenterology and Hepatology

    Research

    Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease

    2026

    Via The Lancet Regional Health. Europe

    Research

    Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes

    2026

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

    2026

    Via Gastroenterology

    Research

    High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

    2026

    Via Diabetes, Obesity & Metabolism

    Research

    The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH

    2026

    Via Expert Review of Pharmacoeconomics & Outcomes Research

    Research

    Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption

    2026

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

    2025

    Via Frontiers in Endocrinology

    Research

    Population-Based vs Health System and Insurer Records: Significant Underdiagnosis of PCOS

    2025

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

    2025

    Via Journal of Hepatology

    Research

    Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise

    2025

    Via Journal of the Endocrine Society

    Research

    Will a "multivitamin" a day keep the "MASLD doctor" away?

    2025

    Via Metabolism and Target Organ Damage

    Research

    Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus

    2025

    Via The Journal of Clinical Endocrinology and Metabolism